Search details
1.
Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia.
Proc Natl Acad Sci U S A
; 119(27): e2123227119, 2022 07 05.
Article
in English
| MEDLINE | ID: mdl-35759659
2.
Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
Proc Natl Acad Sci U S A
; 117(30): 17785-17795, 2020 07 28.
Article
in English
| MEDLINE | ID: mdl-32651270
3.
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Proc Natl Acad Sci U S A
; 116(45): 22609-22618, 2019 11 05.
Article
in English
| MEDLINE | ID: mdl-31591209
4.
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Clin Cancer Res
; 28(7): 1313-1322, 2022 04 01.
Article
in English
| MEDLINE | ID: mdl-35091444
5.
Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.
Adv Cancer Res
; 141: 213-253, 2019.
Article
in English
| MEDLINE | ID: mdl-30691684
Results
1 -
5
de 5
1
Next >
>>